Back to search

France· FR:60635068

IDARUBICINE ACCORD 5 mg/5 ml, solution pour perfusion

A idarubicin product containing chlorhydrate d'idarubicine, registered in France by ACCORD HEALTHCARE FRANCE. The same ATC class is registered in 17 of our 19 countries.

ATC L01DB06

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedIDARUBICINE ACCORD 5 mg/5 ml, solutio…ATCL01DB06REGISTER NO.FR:60635068PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Idarubicin is registered in 17 of 19 countries.

Countries holding a registration under ATC L01DB06 (idarubicin), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 10 of them publish a price we can compare per daily dose

Idarubicin · ATC L01DB06

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
CHLORHYDRATE D'IDARUBICINE
Manufacturer
ACCORD HEALTHCARE FRANCE
Country
France (FR)
ATC code
L01DB06
ATC class
Idarubicin
Defined daily dose
6 mg, O
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400955057185
    1 flacon en verre de 5 mL

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

435 interactions on record for idarubicin.

Graded by severity as the source publishes them — 98 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Idarubicin · interactions on record

435 records

  • 98 severe
  • 328 moderate
  • 9 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • QuinidineC01BA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Idarubicin in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All idarubicin products

Authorised across Europe · EMA

The same active substance is authorised in 27 EEA countries. Names it is sold under:

  • Austria · Idarubicin Ebewe, Idarubicin Hexal
  • Belgium · Zavedos
  • Bulgaria · Заведос
  • Cyprus · Zavedos
  • Czechia · Zavedos
  • Germany · Idarubicin Hexal, Idarubicin Hikma
  • Denmark · Zavedos
  • Spain · Idarubicina Sandoz, Zavedos
  • Finland · Idarubicin Accord, Zavedos
  • United Kingdom (Northern Ireland) · Idarubicin Accord Healthcare, Idarubicin Sandoz
  • Greece · Zacorist, Zavedos
  • Croatia · Zavedos
  • Hungary · Zavedos
  • Ireland · Zavedos
  • Iceland · Zavedos
  • Italy · Zavedos
  • Lithuania · Zavedos
  • Luxembourg · Zavedos
  • Latvia · Zavedos
  • Netherlands · Zavedos
  • Norway · Zavedos
  • Poland · Idarubicin Accord, Zavedos
  • Portugal · Idarrubicina Accord, Idarrubicina Azevedos
  • Romania · Zavedos
  • Sweden · Zavedos
  • Slovenia · Zavedos
  • Slovakia · Zavedos

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/18e4290b-9867-4755-982a-ecc7169a940e
GET /v1/drugs/18e4290b-9867-4755-982a-ecc7169a940e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "60635068",
  "date_amm": "2018-07-05",
  "type_amm": "Procédure de reconnaissance mutuelle",
  "numero_ue": null,
  "substance": "CHLORHYDRATE D'IDARUBICINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution pour perfusion",
  "voies_administration": "intraveineuse",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about idarubicin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.